PaySign, Inc. (NASDAQ:PAYS) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Corporate Participants Mark Newcomer - Co-Founder, Chairman and Chief Executive Officer Jeff Baker - Chief Financial Officer Conference Call Participants Gary Prestopino - Barrington Research Operator Hello and welcome to the PaySign Third Quarter 2022 Earnings Conference Call. As a reminder, this conference call is being recorded. This call may include statements that may be deemed to be forward-looking under federal s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

PaySign, Inc. (NASDAQ:PAYS) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Matthew Turner - Vice President & Head of Patient Affordability Solutions Jeff Baker - Chief Financial Officer & Treasurer Mark Newcomer - Co-Founder, Vice-Chairman & Chief Executive Officer Conference Call Participants Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Thalman Operator Hello and welcome to the PaySign Second Quarter 2022 Earnings Conference Call. As a reminder, this confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 (Sta ...

PaySign, Inc. (NASDAQ:PAYS) Q1 2022 Earnings Conference Call May 11, 2022 5:00 PM ET Company Participants Mark Newcomer - Chief Executive Officer Jeff Baker - Chief Financial Officer Conference Call Participants Gary Prestopino - Barrington Operator Hello, and welcome to the PaySign First Quarter 2022 Earnings Conference Call. As a reminder this conference is being recorded. This presentation may include comments that may be deemed to be forward-looking statements under federal securities laws and the compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐TRANSITION PURSUANT TO UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-38623 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 ...

PaySign, Inc. (NASDAQ:PAYS) Q4 2021 Earnings Conference Call March 22, 2022 5:00 PM ET Company Participants Mark Newcomer – Chief Executive Officer Jeff Baker – Chief Financial Officer Conference Call Participants Peter Heckmann – D.A. Davidson Operator Hello, and welcome to the Paysign Fourth Quarter 2021 Earnings Conference Call. As a reminder, this conference is being recorded. This presentation may include forward-looking statements to the extent that the information is presented in this presentation di ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 ...

Financial Data and Key Metrics Changes - The company reported net revenue of $7.8 million for Q3 2021, an increase of $7.9 million year-over-year and a sequential increase of $1.1 million or 16.8% [7] - Adjusted EBITDA for the quarter was $955,000, representing a nearly threefold increase compared to Q2 2021 [7] - Gross margin for the quarter was 51.1%, supported by the conclusion of two pharmaceutical programs [19] - The net loss for the quarter was $271,000, with total operating expenses at $4.2 million [20] Business Line Data and Key Metrics Changes - Plasma revenue accounted for $7 million, up $1.8 million from the same period last year, with an average revenue per month per plasma center of $6,542 [18][22] - Pharma revenue for Q3 2021 was $660,000, an increase of $6 million compared to Q3 2020, driven by changes in accounting estimates [18][23] - The patient affordability vertical saw the launch of three new programs during the quarter, with additional programs expected to launch in Q4 [10][12] Market Data and Key Metrics Changes - Total gross funds loaded increased by 24.7% year-over-year and 7.6% sequentially [8] - Plasma gross funds loaded increased by 42.7% year-over-year and 10.3% from the previous quarter [8] - The company ended the quarter with 359 plasma centers, having onboarded seven additional centers [9][22] Company Strategy and Development Direction - The company aims to bridge gaps left by competitors by leveraging its unique capabilities at the intersection of FinTech and healthcare [15] - Continued investments in patient affordability products and personnel are planned to support growth [12][25] - The company expects to onboard a total of 10 additional plasma centers by the end of the year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth in both plasma and patient affordability segments, despite ongoing challenges from the pandemic [14] - The company anticipates total revenue for the full year to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [27] - Adjusted EBITDA guidance for the full year has been increased to a range of $1.3 million to $1.9 million [27] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt, indicating a solid financial position [26] - Depreciation and amortization expenses are expected to be approximately $2.5 million for the full year [29] Q&A Session Summary - No specific questions or answers were recorded in the provided content, as the call concluded without a Q&A segment [31][32]

1 Transforming What Payments Can Do for You NASDQ: PAYS • 8/5/2021 © 2021 Paysign, Inc. All rights reserved. Paysign® is a registered trademark. ● ● ●● ● ● ● ● yood ● ● ● ● · Who Is Paysign? The content of this document is propriety and confidential information of Paysign, hc. It is not intended to be distributed to any third party without the written consent Thi card sped by Patht: Bank M.A., Nember BDC, prosunt to allense from 1991US A., ht. This ard and ouse exey where Was debt cards re scepted. Use of t ...